Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis
Fernando Bril, Diana Barb, Romina Lomonaco et al. · Journal of Hepatology · 2019
Cited by 54 works. doi:10.1016/j.jhep.2019.09.018
Authors
References
- Standards of Medical Care in Diabetes
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic Steatohepatitis
- Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis